Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 11, 2004, Pages 2051-2056

  Loike, J D ^a   Shabtai, D Y ^a   Neuhut, R ^a   Malitzky, S ^a   Lu, E ^a   Husemann, J ^a   Goldberg, I J ^a   Silverstein, S C ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

Cell activation; Lovastatin; Monocytes and macrophages; Phagocytosis

Indexed keywords

CHOLESTEROL; FARNESYL DIPHOSPHATE; FC RECEPTOR; GERANYLGERANYL PYROPHOSPHATE; ISOPRENOID; LIPOPOLYSACCHARIDE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; MEVINOLIN; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; STATINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; ZARAGOZIC ACID A;

ANIMAL CELL; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHROCYTE; HUMAN; HUMAN CELL; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELLS, CULTURED; CHOLESTEROL; EXTRACELLULAR MATRIX; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LIPOPROTEINS; LOVASTATIN; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; PINOCYTOSIS; RECEPTORS, FC; SIMVASTATIN; TRICARBOXYLIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA; VACUOLES;

EID: 8344259034     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000143858.15909.29     Document Type: Article

References (36)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217.
2. Hanke H, Lenz C, Finking G. The discovery of the pathophysiological aspects of atherosclerosis - a review. Acta Chir Belg. 2001;101:162-169.
3. Mora R, Lupu F, Simionescu N. Cytochemical localization of beta-lipoproteins and their components in successive stages of hyperlipidemic atherogenesis of rabbit aorta. Atherosclerosis. 1989;79:183-195.
4. Wright RS, Murphy JG, Bybee KA, Kopecky SL, LaBlanche JM. Stalin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin Proc. 2002;77:1085-1092.
5. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
6. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Froland SS, Semb AG, Aukrust P. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol. 2003;41:1460-1467.
7. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM, Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
8. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol. 2001;87:446-448, A446.
9. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, Valent P, Binder BR, Minar E, Baghestanian M. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003;23:397-403.
10. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
11. Umetani N, Kanayama Y, Okamura M, Negoro N, Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta. 1996;1303:199-206.
12. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001;1:105-118.
13. Mach F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb Haemost. 2003;90:607-610.
14. Ballantyne CM. Statins after cardiac transplantation: which statin, what dose, and how low should we go? J Heart Lung Transplant. 2000;19:515-517.
15. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol. 2002;22:1029-1035.
16. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105:1756-1759.
17. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
18. Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranyl pyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci. 2003;17:93-102.
19. Le Y, Gong W, Shen W, Li B, Dunlop NM, Wang JM. A burgeoning family of biological mediators: chemokines and chemokine receptors. Arch Immunol Ther Exp. 2000;48:143-150.
20. Cox D, Greenberg S. Phagocytic signaling strategies: Fc(gamma)receptor- mediated phagocytosis as a model system. Semin Immunol. 2001;13:339-345.
21. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, Bansal VS, Dufresne C, VanMiddlesworth FL, Hensens OD, et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci U S A. 1993;90:80-84.
22. Husemann J, Obstfeld A, Febbraio M, Kodama T, Silverstein SC. CD11b/CD18 mediates production of reactive oxygen species by mouse and human macrophages adherent to matrixes containing oxidized LDL. Arterioscler Thromb Vasc Biol. 2001;21:1301-1305.
23. Loike JD, Cao L, Budhu S, Hoffman S, Silverstein SC. Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins. J Immunol. 2001;166:7534-7542.
24. Loike JD, Kozler VF, Silverstein SC. Increased ATP and creatine phosphate turnover in phagocytosing mouse peritoneal macrophages. J Biol Chem. 1979;254:9558-9564.
25. Swanson JA, Yirinec BD, Silverstein SC. Phorbol esters and horseradish peroxidase stimulate pinocytosis and redirect the flow of pinocytosed fluid in macrophages. J Cell Biol. 1985;100:851-859.
26. Johannes L, Lamaze C. Clathrin-dependent or not: is it still the question? Traffic. 2002;3:443-451.
27. Werb Z, Cohn ZA. Cholesterol metabolism in the macrophage. 3. Ingestion and intracellular fate of cholesterol and cholesterol esters. J Exp Med. 1972;135:21-44.
28. Muhlestein JB. Secondary prevention of coronary artery disease with antimicrobials: current status and future directions. Am J Cardiovasc Drugs. 2002;2:107-118.
29. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J. 1993;14(suppl K):118-124.
30. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203-214.
31. Greenberg S. Diversity in phagocytic signaling. J Cell Sci. 2001;114:1039-1040.
32. Kwiatkowska K, Frey J, Sobota A. Phosphorylation of FcgammaRIIA is required for the receptor-induced actin rearrangement and capping: the role of membrane rafts. J Cell Sci. 2003;116:537-550.
33. Hillyard DZ, Jardine AG, McDonald KJ, Cameron AJ. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis. 2004;172:219-228.
34. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106:2041-2042.
35. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109:II18-26.
36. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy Circulation. 2004.